Eltrapuldencel-T

Drug Profile

Eltrapuldencel-T

Alternative Names: Autologous stem cell therapy - California Stem Cell; Cancer stem cell - California Stem Cell; CLBS 20; DC-TC; DC/DT; MAC-VAC; Malignant melanoma stem cell therapy - NeoStem Oncology; Melapuldencel-T; NBS 20

Latest Information Update: 06 Mar 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Hoag Memorial Hospital Presbyterian
  • Developer Caladrius Biosciences
  • Class Cancer vaccines; Dendritic cell vaccines; Immunotherapies; Stem cell therapies
  • Mechanism of Action Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Malignant melanoma
  • New Molecular Entity No
  • Available For Licensing Yes - Colorectal cancer; Liver cancer; Lung cancer; Ovarian cancer

Highest Development Phases

  • Discontinued Malignant melanoma

Most Recent Events

  • 25 Apr 2016 Caladrius Biosciences terminates a phase III trial for Malignant melanoma (late-stage disease) in USA (NCT01875653)
  • 08 Jun 2015 NeoStem is now called Caladrius Biosciences
  • 08 Jun 2015 Caladrius Biosciences initiates enrolment in the Intus trial for Malignant melanoma in USA (SC) (NCT01875653)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top